L-DOPA-d6
Based on 1 Customer Validation
L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.48%
- No. CAS: 713140-75-1
- Fòrmula: C9H5D6NO4
- Peso molecular:203.22
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas Dopamine Receptor
MoreVer todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
Descripciòn
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Aplicación
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
No. CAS 713140-75-1
-
Unlabeled CAS 59-92-7
-
Appearance Solid
-
Peso molecular 203.22
-
Fòrmula C9H5D6NO4
-
Color White to off-white
-
SMILES
OC([C@](N)([2H])C([2H])([2H])C1=C([2H])C(O)=C(C([2H])=C1[2H])O)=O
-
Synonyms
Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
0.1 M HCl : 20 mg/mL (98.42 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)
H2O : 1 mg/mL (4.92 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [Content Brief]
[3]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7. [Content Brief]
[4]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237. [Content Brief]
[5]. Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / 0.1 M HCl | 1 mM | 4.9208 mL | 24.6039 mL | 49.2078 mL | 123.0194 mL |
| 0.1 M HCl | 5 mM | 0.9842 mL | 4.9208 mL | 9.8416 mL | 24.6039 mL |
| 10 mM | 0.4921 mL | 2.4604 mL | 4.9208 mL | 12.3019 mL | |
| 15 mM | 0.3281 mL | 1.6403 mL | 3.2805 mL | 8.2013 mL | |
| 20 mM | 0.2460 mL | 1.2302 mL | 2.4604 mL | 6.1510 mL | |
| 25 mM | 0.1968 mL | 0.9842 mL | 1.9683 mL | 4.9208 mL | |
| 30 mM | 0.1640 mL | 0.8201 mL | 1.6403 mL | 4.1006 mL | |
| 40 mM | 0.1230 mL | 0.6151 mL | 1.2302 mL | 3.0755 mL | |
| 50 mM | 0.0984 mL | 0.4921 mL | 0.9842 mL | 2.4604 mL | |
| 60 mM | 0.0820 mL | 0.4101 mL | 0.8201 mL | 2.0503 mL | |
| 80 mM | 0.0615 mL | 0.3075 mL | 0.6151 mL | 1.5377 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
L-DOPA-d6 Related Classifications
HY-N0304S Related Classifications
Powered by Bioz